375 related articles for article (PubMed ID: 27228981)
1. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care.
Wetmore JB; Tzivelekis S; Collins AJ; Solid CA
BMC Nephrol; 2016 May; 17(1):53. PubMed ID: 27228981
[TBL] [Abstract][Full Text] [Related]
2. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
[TBL] [Abstract][Full Text] [Related]
3. Does One Size Fit All With the Effects of Payment Reform? Dialysis Facility Payer Mix and Anemia Management Under the Expanded Medicare Prospective Payment System.
Mukhopadhyay P; Pearson J; Cogan C; Gaber C; Gillespie BW; Turenne M
Med Care; 2019 Aug; 57(8):584-591. PubMed ID: 31295188
[TBL] [Abstract][Full Text] [Related]
4. Blood transfusion practices in dialysis patients in a dynamic regulatory environment.
Hirth RA; Turenne MN; Wilk AS; Wheeler JR; Sleeman KK; Zhang W; Paul MA; Nahra TA; Messana JM
Am J Kidney Dis; 2014 Oct; 64(4):616-21. PubMed ID: 24560166
[TBL] [Abstract][Full Text] [Related]
5. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
7. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
[TBL] [Abstract][Full Text] [Related]
9. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
[TBL] [Abstract][Full Text] [Related]
10. Development of a standardized transfusion ratio as a metric for evaluating dialysis facility anemia management practices.
Liu J; Li S; Gilbertson DT; Monda KL; Bradbury BD; Collins AJ
Am J Kidney Dis; 2014 Oct; 64(4):608-15. PubMed ID: 24820317
[TBL] [Abstract][Full Text] [Related]
11. Medicare program; end-stage renal disease prospective payment system. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2010 Aug; 75(155):49029-214. PubMed ID: 20712086
[TBL] [Abstract][Full Text] [Related]
12. Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates.
Molony JT; Monda KL; Li S; Beaubrun AC; Gilbertson DT; Bradbury BD; Collins AJ
Am J Kidney Dis; 2016 Aug; 68(2):266-276. PubMed ID: 26980607
[TBL] [Abstract][Full Text] [Related]
13. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
[TBL] [Abstract][Full Text] [Related]
14. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis.
Hornberger J; Hirth RA
Am J Kidney Dis; 2012 Aug; 60(2):280-7. PubMed ID: 22560829
[TBL] [Abstract][Full Text] [Related]
15. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
[TBL] [Abstract][Full Text] [Related]
16. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
17. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management?
Turenne MN; Cope EL; Porenta S; Mukhopadhyay P; Fuller DS; Pearson JM; Dahlerus C; Lantz B; Tentori F; Robinson BM
J Am Soc Nephrol; 2015 Mar; 26(3):754-64. PubMed ID: 25300289
[TBL] [Abstract][Full Text] [Related]
18. Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis.
Spoendlin J; Schneeweiss S; Tsacogianis T; Paik JM; Fischer MA; Kim SC; Desai RJ
Am J Kidney Dis; 2018 Aug; 72(2):178-187. PubMed ID: 29891194
[TBL] [Abstract][Full Text] [Related]
19. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.
Monda KL; Joseph PN; Neumann PJ; Bradbury BD; Rubin RJ
BMC Nephrol; 2015 May; 16():67. PubMed ID: 25928734
[TBL] [Abstract][Full Text] [Related]
20. Economic and organizational impact of the changing hospital funding practices of erythropoiesis-stimulating agents on the management of care of dialysis patients in France.
Therasse C; Fusier I; Cordonnier AL; Bérard F; de Curzon OP; Bocquet F; Paubel P
J Comp Eff Res; 2018 Jun; 7(6):569-580. PubMed ID: 29537304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
